HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on VYNE Therapeutics (NASDAQ:VYNE) and maintained a price target of $28.
August 14, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VYNE Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $28.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for VYNE Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100